CLINICAL_TRIALS
trial_result
· 2010-12-20
Clinical Trial Update: Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking [Phase 2]
Summary
Phase 2 trial evaluating GW468816, an NMDA glycine site antagonist, for prevention of relapse to smoking; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Nicotine Dependence | Phase 2 | Status: COMPLETED | Results posted: 2010-12-20